TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales

TG Therapeutics

03/08/2026 12:13

Overview
U.S. biotech's Q2 product revenue rose 70% yr/yr, driven by BRIUMVI sales
Q2 net income and EPS declined from prior year as expenses increased
Company raised full-year 2026 revenue guidance on BRIUMVI momentum

Outlook
Company raises full-year 2026 total global revenue target to about $950 mln
TG Therapeutics raises 2026 BRIUMVI U.S. net product revenue target to $890-$905 mln
Company expects 2026 operating expense of $350-$400 mln, excluding non-cash compensation

Result Drivers
BRIUMVI SALES GROWTH - Co said Q2 revenue growth was driven by a 64% yr/yr increase in U.S. BRIUMVI net product revenue
COMMERCIALIZATION EXPENSES - Co attributed higher SG&A costs to increased marketing, media spend, and personnel for BRIUMVI commercialization
PIPELINE AND MANUFACTURING COSTS - Co said higher R&D expenses were due to subcutaneous BRIUMVI manufacturing and expanded clinical trial activity

Company press release: ID:nGNXbMKcG1

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$235.79 mln
 
Q2 EPS
 
$0.05
 
Q2 Net Income
 
$7.78 mln
 
Q2 Operating Income
 
$21.67 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for TG Therapeutics Inc is $74.00, about 42.2% above its July 31 closing price of $52.03
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
Aug 3 - Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
July 31 - Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision
July 31 - Tenax Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)